Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial

• Published in: PloS one Vol. 12; no. 2; p. e0169965
• Main Authors: Ciesielska, Agnieszka, Samaranch, Lluis, San Sebastian, Waldy, Dickson, Dennis W., Goldman, Samuel, Forsayeth, John, Bankiewicz, Krystof S.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.02.2017; Public Library of Science (PLoS)
• Subjects: AADC gene; Aged; Aged, 80 and over; Amino acids; Animal models; Animals; Aromatic-L-amino-acid decarboxylase; Aromatic-L-Amino-Acid Decarboxylases - genetics; Aromatic-L-Amino-Acid Decarboxylases - metabolism; Biology and Life Sciences; Brain research; Care and treatment; Caudate nucleus; Caudate Nucleus - metabolism; Conversion; Corpus Striatum - metabolism; Dependovirus - genetics; Dependoviruses; Dihydroxyphenylalanine; Disease control; Disease Models, Animal; Dopamine; Dopamine - metabolism; Dopamine receptors; Enzyme Activation; Female; Gene therapy; Genetic Therapy; Genetic Vectors - genetics; Humans; Levodopa; Levodopa - metabolism; Levodopa - therapeutic use; Macaca mulatta; Male; Medicine and Health Sciences; Metabolites; Movement disorders; MPTP; Neostriatum; Neurodegenerative diseases; Nuclei; Parkinson disease; Parkinson Disease - genetics; Parkinson Disease - metabolism; Parkinson Disease - therapy; Parkinson's disease; Patients; Putamen; Putamen - metabolism; Rats; Regional analysis; Regional planning; Rodents; Serotonin; Studies; Tissue analysis
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0169965

In Parkinson's disease (PD), aromatic L-amino acid decarboxylase (AADC) is the rate-limiting enzyme in the conversion of L-DOPA (Sinemet) to dopamine (DA). Previous studies in PD animal models demonstrated that lesion of dopaminergic neurons is associated with profound loss of AADC activity in the striatum, blocking efficient conversion of L-DOPA to DA. Relatively few studies have directly analyzed AADC in PD brains. Thus, the aim of this study was to gain a better understanding of regional changes in AADC activity, DA, serotonin and their monoamine metabolites in the striatum of PD patients and experimentally lesioned animals (rat and MPTP-treated nonhuman primate, NHP). Striatal AADC activity was determined post mortem in neuropathologically confirmed PD subjects, animal models and controls. A regional analysis was performed for striatal AADC activity and monoamine levels in NHP tissue. Interestingly, analysis of putaminal AADC activity revealed that control human striatum contained much less AADC activity than rat and NHP striata. Moreover, a dramatic loss of AADC activity in PD striatum compared to controls was detected. In MPTP-treated NHP, caudate nucleus was almost as greatly affected as putamen, although mean DA turnover was higher in caudate nucleus. Similarly, DA and DA metabolites were dramatically reduced in different regions of PD brains, including caudate nucleus, whereas serotonin was relatively spared. After L-DOPA administration in MPTP-treated NHP, very poor conversion to DA was detected, suggesting that AADC in NHP nigrostriatal fibers is mainly responsible for L-DOPA to DA conversion. These data support further the rationale behind viral gene therapy with AAV2-hAADC to restore AADC levels in putamen and suggest further the advisability of expanding vector delivery to include coverage of anterior putamen and the caudate nucleus.